Nutriband Inc. Advances Aversa Fentanyl to Commercial Manufacturing Scale with Kindeva
TL;DR
Nutriband's Aversa Fentanyl patch, developed with Kindeva, offers a competitive edge as the first abuse-deterrent opioid patch, targeting peak U.S. sales of $80-$200 million.
Nutriband and Kindeva scaled up Aversa Fentanyl's manufacturing, combining AVERSA technology with an FDA-approved fentanyl patch, next steps include clinical supplies and an IND application.
Aversa Fentanyl's abuse-deterrent technology aims to reduce opioid misuse, contributing to a safer healthcare environment and better patient outcomes globally.
Discover how Nutriband's innovative AVERSA technology is set to revolutionize opioid treatment with the world's first abuse-deterrent fentanyl patch.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc. (NASDAQ: NTRB), in collaboration with Kindeva, has achieved a milestone in the development of Aversa Fentanyl by successfully scaling up its commercial manufacturing process. This development is pivotal as Aversa Fentanyl aims to be the world's first abuse-deterrent opioid patch, integrating Nutriband's AVERSA technology with Kindeva's FDA-approved fentanyl patch. The collaboration leverages Kindeva's expertise in drug-device combinations and its U.S.-based transdermal facility to produce the patch.
The significance of this advancement lies in its potential to mitigate the opioid crisis by preventing the abuse, misuse, and accidental exposure of fentanyl, a potent opioid with high abuse potential. With the next steps involving the production of clinical supplies and submission of an Investigational New Drug application for a human abuse liability study, Aversa Fentanyl is on a path that could redefine opioid therapy. Nutriband projects peak U.S. sales between $80 million and $200 million, highlighting the commercial and therapeutic potential of this innovation.
This development is not just a breakthrough for Nutriband and Kindeva but also represents a critical step forward in the fight against opioid abuse. By offering a solution that deters abuse while providing pain relief, Aversa Fentanyl could significantly impact the pharmaceutical industry and public health, offering a safer alternative to traditional opioid treatments.
Curated from InvestorBrandNetwork (IBN)
